Skip to main content

SMARCA4-deficient Malignant Tumors clinical trials at UCSF

1 research study open to eligible people

SMARCA4-deficient malignant tumors are a type of cancer. UCSF is studying how two drugs, nivolumab and ipilimumab, can help treat these tumors in children and young adults. This research is currently open for people to join.

Showing trials for

Our lead scientists for SMARCA4-deficient Malignant Tumors research studies include .

Last updated: